Ekso Bionics Reports Q3 2025 Revenue Increase Amid Operational Challenges

Ekso Bionics Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a modest increase in revenue but continued operational challenges. The company generated $4.2 million in revenue for the three months ended September 30, 2025, a 2% increase from $4.1 million in the same period last year. However, for the nine months ended September 30, 2025, revenue decreased by 25% to $9.7 million, down from $12.8 million in the prior year. The decline was primarily attributed to reduced sales in the EMEA region, although there was an uptick in sales volume in the Americas, particularly from multiple-device contracts for the EksoNR.

The company's gross profit for the third quarter increased to $2.5 million, up from $2.2 million a year earlier, resulting in a gross margin of 60%, compared to 53% in the prior year. This improvement was driven by lower device costs associated with high-margin sales. Operating expenses decreased significantly, totaling $4.0 million for the quarter, down from $4.8 million in the same period last year, largely due to reduced sales and marketing expenses and lower research and development costs. As a result, the loss from operations narrowed to $1.4 million, compared to a loss of $2.6 million in the third quarter of 2024.

In terms of strategic developments, Ekso Bionics has been actively pursuing partnerships and exploring potential acquisitions to enhance its market position. The company is also focused on expanding its Personal Health market, particularly following the approval of Medicare reimbursement for the Ekso Indego Personal device, which is expected to drive demand. The company has signed agreements with several Durable Medical Equipment suppliers to facilitate sales and reimbursement processes, indicating a strategic shift towards enhancing its distribution channels.

Operationally, the company reported a cash balance of $2.7 million as of September 30, 2025, a decrease from $8.3 million at the end of the previous year. The decline in cash was attributed to ongoing operational losses and the need for additional funding to support its operations. The company has indicated that it may need to raise funds through various financing options, including equity offerings and debt financing, to meet its cash requirements over the next 12 months. Management has expressed concerns about the company's ability to continue as a going concern, given the significant accumulated deficit of $257.7 million and the expectation of continued operating losses.

Looking ahead, Ekso Bionics aims to increase its revenue through enhanced marketing efforts and by optimizing its reimbursement submission processes. The company anticipates that while the majority of its revenue will continue to come from Enterprise Health sales, contributions from Personal Health products will grow as it refines its sales strategies and expands its market reach. The management remains cautious about the economic environment and competitive pressures but is committed to pursuing growth opportunities in both existing and new markets.